[Skip to Navigation]
April 29, 2020

Use of Etanercept in a Series of Pediatric Patients With Stevens-Johnson Syndrome–Toxic Epidermal Necrolysis Spectrum Disease

Author Affiliations
  • 1Department of Dermatology, NewYork-Presbyterian/Weill Cornell Medical Center, New York, New York
  • 2Lincoln Medical Center, New York, New York
JAMA Dermatol. 2020;156(8):921-922. doi:10.1001/jamadermatol.2019.3731

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening adverse drug reactions that manifest with full-thickness epidermal necrosis and are often accompanied by fever and other systemic symptoms.1,2 These entities exist on a disease spectrum (herein referred to as SJS-TEN) based on percentage of body surface area with denuded skin.3 Given the rarity of SJS-TEN in the pediatric population, there is no clear, evidence-based therapeutic recommendation beyond discontinuation of the harmful medication and burn-level supportive care.

Add or change institution